Insider Selling: Sera Prognostics (NASDAQ:SERA) CFO Sells $11,315.20 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 5,440 shares of Sera Prognostics stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $2.08, for a total transaction of $11,315.20. Following the completion of the transaction, the chief financial officer owned 303,227 shares in the company, valued at approximately $630,712.16. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sera Prognostics Stock Performance

NASDAQ SERA opened at $1.87 on Friday. The firm has a market cap of $73.23 million, a PE ratio of -2.88 and a beta of 0.94. Sera Prognostics, Inc. has a one year low of $1.56 and a one year high of $4.09. The firm’s fifty day moving average is $2.02 and its two-hundred day moving average is $2.54.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.07 million. Sera Prognostics had a negative net margin of 56,385.97% and a negative return on equity of 41.02%. Research analysts predict that Sera Prognostics, Inc. will post -0.58 earnings per share for the current year.

Analyst Upgrades and Downgrades

SERA has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Sera Prognostics in a research note on Friday, March 27th. Craig Hallum initiated coverage on shares of Sera Prognostics in a research note on Thursday, June 4th. They issued a “buy” rating and a $6.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.50.

Institutional Trading of Sera Prognostics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Arkadios Wealth Advisors purchased a new stake in shares of Sera Prognostics in the first quarter valued at about $25,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Sera Prognostics in the fourth quarter valued at about $31,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Sera Prognostics in the third quarter valued at about $38,000. Lido Advisors LLC purchased a new stake in shares of Sera Prognostics in the third quarter valued at about $68,000. Finally, Cetera Investment Advisers purchased a new stake in shares of Sera Prognostics in the fourth quarter valued at about $74,000. Hedge funds and other institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.